AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%
Last update at 2024-04-22T20:11:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 4232.40M | 2730.40M | 3116.80M | 1394.92M | 600.24M |
| Minority interest | - | - | 0.00000M | 0.00000M | -9.79300M |
| Net income | 3322.00M | 2342.10M | 2711.65M | 1176.81M | 2096.90M |
| Selling general administrative | 887.20M | 840.10M | 770.46M | 658.50M | 557.62M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 7850.40M | 6670.20M | 5469.38M | 3615.06M | 2638.06M |
| Reconciled depreciation | 148.30M | 125.60M | 109.52M | 106.94M | 72.42M |
| Ebit | 4307.40M | 2782.10M | 2856.29M | 1197.57M | 590.76M |
| Ebitda | 4345.20M | 2788.80M | 3188.05M | 1457.88M | 663.18M |
| Depreciation and amortization | 37.80M | 6.70M | 331.76M | 260.31M | 72.42M |
| Non operating income net other | -20.20000M | 9.80M | 318.66M | 255.85M | -0.79000M |
| Operating income | 4307.40M | 2782.10M | 2856.29M | 1197.57M | 635.15M |
| Other operating expenses | 4565.30M | 4795.40M | 3336.29M | 2960.80M | 2383.63M |
| Interest expense | 54.80M | 61.50M | 58.15M | 58.50M | 34.12M |
| Tax provision | 910.40M | 388.30M | 405.15M | 218.11M | -1486.86200M |
| Interest income | 144.60M | 4.90M | 22.24M | 63.68M | 33.50M |
| Net interest income | 89.80M | -56.60000M | -35.91200M | 5.18M | -34.11900M |
| Extraordinary items | - | - | - | - | 1560.00M |
| Non recurring | 115.50M | - | - | - | 28.82M |
| Other items | - | - | - | - | - |
| Income tax expense | 910.40M | 388.30M | 405.15M | 218.11M | -1486.86200M |
| Total revenue | 8930.70M | 7574.40M | 6205.68M | 4162.82M | 3047.60M |
| Total operating expenses | 3485.00M | 3891.20M | 2599.99M | 2413.04M | 1974.09M |
| Cost of revenue | 1080.30M | 904.20M | 736.30M | 547.76M | 409.54M |
| Total other income expense net | -75.00000M | -51.70000M | 260.51M | 197.35M | -29.60600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 3322.00M | 2342.10M | 2711.65M | 1176.81M | 2087.10M |
| Net income applicable to common shares | 3322.00M | 2342.10M | 2711.65M | 1176.81M | 2096.90M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 18150.90M | 13432.50M | 11751.81M | 8318.47M | 6245.90M |
| Intangible assets | 603.60M | 400.00M | 400.00M | 400.00M | 50.38M |
| Earning assets | - | - | - | - | - |
| Other current assets | 74.40M | 187.20M | 308.35M | 213.51M | 74.05M |
| Total liab | 4238.20M | 3332.50M | 3064.99M | 2233.22M | 1810.69M |
| Total stockholder equity | 13912.70M | 10100.00M | 8686.82M | 6085.24M | 4435.20M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1877.70M | 1460.00M | 1171.02M | 1024.29M | 40.59M |
| Common stock | 2.60M | 2.50M | 2.60M | 2.59M | 2.55M |
| Capital stock | 2.60M | 2.50M | 2.60M | 2.59M | 2.55M |
| Retained earnings | 6522.80M | 3200.80M | 858.67M | -1852.97800M | -2989.47800M |
| Other liab | 685.80M | 902.20M | 923.41M | 275.53M | 108.85M |
| Good will | 1088.00M | 1402.20M | 1402.16M | 1402.16M | 50.38M |
| Other assets | 1422.70M | 986.90M | 587.03M | 1199.40M | 1540.40M |
| Cash | 10504.00M | 6795.00M | 5988.19M | 3109.32M | 2650.13M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2430.60M | 1873.60M | 1560.11M | 1204.52M | 715.48M |
| Current deferred revenue | 159.60M | 171.70M | 191.52M | 62.33M | 554.09M |
| Net debt | -9943.00000M | -6238.30000M | -5406.71100M | -2531.95100M | -2082.97100M |
| Short term debt | 89.40M | 46.90M | 42.43M | 30.29M | 9.82M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 561.00M | 556.70M | 581.48M | 577.37M | 567.16M |
| Other stockholder equity | 7386.50M | 6880.80M | 7894.03M | 7937.61M | 7421.48M |
| Property plant equipment | 1455.80M | 1094.10M | 958.53M | 833.28M | 812.00M |
| Total current assets | 12681.30M | 9014.80M | 7825.03M | 4609.31M | 3702.29M |
| Long term investments | - | - | - | 60.80M | 13.60M |
| Net tangible assets | 12221.10M | 8697.80M | 7284.66M | 4683.09M | 4384.82M |
| Short term investments | 274.50M | 729.90M | 670.71M | 698.97M | 518.11M |
| Net receivables | 1442.20M | 1136.80M | 885.35M | 633.52M | 409.69M |
| Long term debt | - | - | - | - | 561.89M |
| Inventory | 460.60M | 353.10M | 280.78M | 167.50M | 124.36M |
| Accounts payable | 303.90M | 195.00M | 155.14M | 87.61M | 110.99M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.80M | 15.90M | -68.48000M | -1.97300M | 0.66M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 2.60M | 2.50M | 2.60M | 2.59M | 2.55M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 6522.80M | 3200.80M | 858.67M | -1852.97800M | -2989.47800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1422.70M | 986.90M | 683.31M | 371.10M | 181.55M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 5469.60M | 4417.70M | 3926.78M | 3709.15M | 2543.61M |
| Capital lease obligations | 471.60M | 556.70M | 581.48M | 538.58M | 19.66M |
| Long term debt total | - | - | 539.04M | 538.58M | 581.55M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 227.30M | -28.90000M | 378.51M | 33.66M | -15.34200M |
| Change to liabilities | 1162.20M | 354.10M | 598.57M | 188.09M | 232.18M |
| Total cashflows from investing activities | -321.10000M | -340.90000M | 99.39M | -1235.31800M | -202.15800M |
| Net borrowings | -85.50000M | -24.40000M | -29.02400M | -35.00500M | -7.08600M |
| Total cash from financing activities | -67.70000M | -1478.00000M | -505.28100M | 126.77M | -71.21900M |
| Change to operating activities | 715.00M | 230.40M | 249.73M | 246.32M | 341.58M |
| Net income | 3322.00M | 2342.10M | 2711.65M | 1176.81M | 2087.10M |
| Change in cash | 3711.90M | 811.20M | 2868.16M | 462.43M | 990.73M |
| Begin period cash flow | 6800.10M | 5988.90M | 3120.68M | 2658.25M | 1667.53M |
| End period cash flow | 10512.00M | 6800.10M | 5988.85M | 3120.68M | 2658.25M |
| Total cash from operating activities | 4129.90M | 2643.50M | 3253.51M | 1569.33M | 1270.29M |
| Issuance of capital stock | - | - | - | 343.24M | 289.29M |
| Depreciation | 148.30M | 125.60M | 109.52M | 106.94M | 72.42M |
| Other cashflows from investing activities | -343.70000M | -77.00000M | -19.32700M | -1193.53100M | -91.29200M |
| Dividends paid | - | -102.00000M | -264.94600M | -10.04600M | 20.84M |
| Change to inventory | -136.40000M | -92.80000M | -132.01400M | -64.04700M | -31.96500M |
| Change to account receivables | -358.60000M | -274.70000M | -223.44400M | -225.58700M | -108.15200M |
| Sale purchase of stock | -172.00000M | -1561.30000M | -739.40700M | -192.01500M | -350.04300M |
| Other cashflows from financing activities | 3.50M | 130.30M | 276.40M | 24.77M | 43.76M |
| Change to netincome | 445.60M | 452.70M | 521.39M | 381.89M | 385.07M |
| Capital expenditures | 204.70M | 235.00M | 259.80M | 75.45M | 95.52M |
| Change receivables | -358.60000M | -274.70000M | -223.44400M | -225.58700M | -108.15200M |
| Cash flows other operating | -453.20000M | -263.50000M | -332.15800M | 5.23M | -1366.36500M |
| Exchange rate changes | - | - | - | - | -6.18200M |
| Cash and cash equivalents changes | 3741.10M | 824.60M | 2847.61M | 460.79M | 990.73M |
| Change in working capital | 340.80M | -105.20000M | -54.45400M | -66.10100M | 238.02M |
| Stock based compensation | 491.30M | 441.40M | 429.46M | 360.49M | 325.05M |
| Other non cash items | 103.40M | -5.80000M | -220.00500M | -176.19600M | 60.02M |
| Free cash flow | 3925.20M | 2408.50M | 2993.70M | 1493.88M | 1174.76M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Inc |
5.64 1.43% | 399.92 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| NVO Novo Nordisk A/S |
2.55 2.08% | 125.26 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.76 3.07% | 126.26 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| CSLLY CSL Ltd |
2.35 2.71% | 89.17 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
| CMXHF CSL Limited |
2.75 1.59% | 176.00 | 41.30 | 26.39 | 6.97 | 5.68 | 7.85 | 26.51 |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
50 Northern Avenue, Boston, MA, United States, 02210
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Exec. Chairman | 1956 |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, Pres & Director | 1973 |
| Mr. Charles F. Wagner Jr. | Exec. VP & CFO | 1968 |
| Mr. Stuart A. Arbuckle B.Sc. | Exec. VP & COO | 1966 |
| Dr. Ourania Tatsis Ph.D. | Exec. VP and Chief Regulatory & Quality Officer | 1971 |
| Ms. Kristen C. Ambrose | Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services | 1977 |
| Dr. David M. Altshuler M.D., Ph.D. | Exec. VP of Global Research & Chief Scientific Officer | 1965 |
| Mr. Mike Tirozzi | SVP and Chief Information & Data Officer | NA |
| Susie Lisa | Sr. VP of Investor Relations | NA |
| Mr. Damian W. Wilmot Esq. | Sr. VP, Chief Risk and Compliance Officer | 1976 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...